PrecivityAD2™
Use
The PrecivityAD2 test provides a comprehensive assessment of Alzheimer's disease pathology by measuring amyloid beta and phosphorylated tau protein levels using mass spectrometry. It supports clinical decision-making by offering predictive value calculations for Alzheimer's disease progression, allowing for personalized treatment approaches.
Special Instructions
Not provided.
Limitations
The test provides risk stratification rather than a definitive diagnosis. The presence of amyloid or tau proteins is not conclusively diagnostic of Alzheimer's and can be influenced by other pathological factors. Patient demographics and comorbid conditions may affect results.
New York Approved
Methodology
Mass Spectrometry (LC-MS/MS)
Biomarkers
Aβ42
Proteinp-tau217
Protein
Result Turnaround Time
10 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
10 mL
Minimum Volume
7 mL
Container
EDTA tube
Collection Instructions
Collect 10 mL of whole blood in a lavender top (EDTA) tube and centrifuge to obtain plasma. Freeze immediately after separation.
Patient Preparation
No fasting required.
Storage Instructions
Plasma should be frozen immediately after separation and kept frozen until analysis.
Causes for Rejection
Gross hemolysis, lipemic samples, or incomplete filling of the collection tube.
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 7 days |
| Frozen | 1 month |